Effects of N-butylscopolammonium bromide on lung function in horses with recurrent airway obstruction.

The research investigated the impact of the drug N-butylscopolammonium bromide on lung functionality in horses with Recurrent Airway Obstruction. It found that the drug acted as a potent bronchodilator, reducing clinical symptoms and lung pressures significantly within 10 minutes of administration, although the effect faded after an hour.

Objective of the Study

• The research aimed to explore the effects of an anticholinergic drug, N-butylscopolammonium bromide (NBB), on the clinical symptoms and lung function in horses diagnosed with Recurrent Airway Obstruction (RAO). RAO is a condition marked by airway inflammation, bronchoconstriction, and excessive mucus production in airways.

Methods Used

• Conducted using a double-blind, placebo-controlled, randomized crossover trial design, the research employed nine horses that had been diagnosed with RAO.
• All participants faced an exposure to moldy hay until a maximum change in transpulmonary pressure of over 15 cm H2O was observed. Following this, the horses were administered either NBB or a placebo solution intravenously.
• Clinical scores and lung function data were recorded initially and at various intervals post-treatment. The horses were then allowed a washout period of six weeks before switching to the opposite treatment.

Results and Conclusions

• The study reported that the administration of NBB led to significant lower clinical scores at 10 and 30 minutes post-administration compared to baseline scores. It also noted a noteworthy decrease in the maximum change in transpulmonary pressure from baseline, starting two minutes post-administration.
• The maximum decline was observed 10 minutes after the drug administration, after which the effect was seen to dissipate. Furthermore, the drug did not differ from the placebo in terms of its impact on transpulmonary pressure values between 60 and 120 minutes post-administration.
• In conclusion, the research establishes NBB as a potent bronchodilator with peak effectivity observed 10 minutes after intravenous administration. This effect however dissipates within 1 hour of drug administration, reaffirming its use as a short-term treatment for RAO in horses.